1. Immunostimulatory bacterial antigen–armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy
- Author
-
Arun Ammayappan, Ianko D. Iankov, Aaron J. Johnson, S. Keith Anderson, Katayoun Ayasoufi, Sotiris Sotiriou, Kyriakos Chatzopoulos, Cheyne Kurokawa, Evanthia Galanis, Kimberly Viker, and Eleni Panagioti
- Subjects
0301 basic medicine ,medicine.medical_treatment ,T cell ,Programmed Cell Death 1 Receptor ,Mice, Nude ,CD8-Positive T-Lymphocytes ,Receptors, Urokinase Plasminogen Activator ,Measles virus ,Translational Research, Biomedical ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Lymphocytes, Tumor-Infiltrating ,Antigen ,Bacterial Proteins ,Cytopathogenic Effect, Viral ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Virotherapy ,Oncolytic Virotherapy ,Antigens, Bacterial ,Mice, Inbred BALB C ,biology ,Cell Death ,business.industry ,Brain Neoplasms ,General Medicine ,Immunotherapy ,Virus Internalization ,biology.organism_classification ,Combined Modality Therapy ,Oncolytic virus ,Mice, Inbred C57BL ,Oncolytic Viruses ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Cancer research ,Cytokines ,Female ,Bacterial antigen ,business ,Glioblastoma ,CD8 ,Research Article - Abstract
Clinical immunotherapy approaches are lacking efficacy in the treatment of glioblastoma (GBM). In this study, we sought to reverse local and systemic GBM-induced immunosuppression using the Helicobacter pylori neutrophil-activating protein (NAP), a potent TLR2 agonist, as an immunostimulatory transgene expressed in an oncolytic measles virus (MV) platform, retargeted to allow viral entry through the urokinase-type plasminogen activator receptor (uPAR). While single-agent murine anti-PD1 treatment or repeat in situ immunization with MV-s-NAP-uPA provided modest survival benefit in MV-resistant syngeneic GBM models, the combination treatment led to synergy with a cure rate of 80% in mice bearing intracranial GL261 tumors and 72% in mice with CT-2A tumors. Combination NAP-immunovirotherapy induced massive influx of lymphoid cells in mouse brain, with CD8(+) T cell predominance; therapeutic efficacy was CD8(+) T cell dependent. Inhibition of the IFN response pathway using the JAK1/JAK2 inhibitor ruxolitinib decreased PD-L1 expression on myeloid-derived suppressor cells in the brain and further potentiated the therapeutic effect of MV-s-NAP-uPA and anti-PD1. Our findings support the notion that MV strains armed with bacterial immunostimulatory antigens represent an effective strategy to overcome the limited efficacy of immune checkpoint inhibitor–based therapies in GBM, creating a promising translational strategy for this lethal brain tumor.
- Published
- 2021